Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209927 | 0.80 | HTR1A (0.35) | — | |
| SCHEMBL3218181 | 0.80 | HTR1A (0.35) | — | |
| SCHEMBL3195075 | 0.80 | HTR1A (0.35) | — | |
| SCHEMBL2687113 | 0.79 | BRD4 (0.43) | CREBBPBRD4 | |
| SCHEMBL2686648 | 0.79 | PRKAB2 (0.39) | — | |
| SCHEMBL2684325 | 0.78 | CA2 (0.39) | MEN1KMT2A | |
| SCHEMBL3213892 | 0.76 | PRKAB2 (0.31) | MEN1KMT2A | |
| SCHEMBL3211902 | 0.76 | PRKAB2 (0.31) | MEN1KMT2A | |
| SCHEMBL3218195 | 0.76 | PRKAB2 (0.31) | MEN1KMT2A | |
| SCHEMBL3218165 | 0.74 | PRKAB2 (0.34) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438050-B9 | NOVEL DERIVATIVES OF ARYL-{4-HALOGENO-4-[AMINOMETHYL]-PIPERIDIN-1-YL}-METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS | PF MEDICAMENT (FR) | 2014-04-23 | — | — | EP | disclosed |
| US-8669250-B2 | Derivatives of aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl}-methanone, their method of preparation and their use as medicinal products | PIERRE FABRE MEDICAMENT (FR) | 2014-03-11 | — | — | US | disclosed |
| EP-2438050-B1 | NOVEL DERIVATIVES OF ARYL-{4-HALOGENO-4-[AMINOMETHYL]-PIPERIDIN-1-YL}-METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS | PF MEDICAMENT (FR) | 2013-08-07 | — | — | EP | disclosed |
| US-20120115860-A1 | NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115860-A1 | NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS | CYP11B1, CYP11B2, CYP3A43 | CREBBP 2187/4885BRD4 1520/4885MEN1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.